Abstract：Objective: To investigate the effects of Leizhuman injection combined with compound Xueshuantong Capsule on the changes of vascular endothelial growth factor, intraocular pressure and visual acuity in patients with age-related macular degeneration. Methods: 60 patients with age-related macular degeneration in our hospital were randomly divided into treatment group and control group, 30 cases in each group. The control group was given intravitreal injection of Leizhumab injection. The treatment groupwas given compound Xueshuantong capsule once a month on the basis of the control group. All patients were treated for 3 months. After treatment, the control group was given intravitreal injection of Leizhumab. Serum levels of vascular endothelial growth factor, CRP, CMT, CNV, intraocular pressure and visual acuity were measured. Results: After treatment, compared with the control group, the serum levels of vascular endothelial growth factor in the treatment groupwere significantly lower (P<0.05); the serum CRP levels in the treatment groupwere significantly lower (P<0.05); the levels of CMT, CNV in the treatment group were lower (P<0.05); The visual acuity (logMAR) and IOP level were significantly lower (P<0.05). Conclusion: The experimental results show that for age-related macular degeneration patients, Leizhumab injection combined with compound Xueshuantong capsule ophthalmic injection can reduce the levels of vascular endothelial growth factor and CRP in peripheral blood, and also reduce the contents of CMT and CNV, so as to lower the ocular blood pressure and improve the visual acuity. It has guiding significance for clinical practice.
2019, Vol. 25 
冀公网安备13080202000677号